In this issue:
Probiotics may have value as an adjunctive therapy for paediatric AD
Obesity facilitates allergic sensitisation by impairing skin barrier function
Ruxolitinib cream improves outcomes in AD
JAK inhibitors linked to a greater risk of infections vs biologics
Proactive vs reactive maintenance after dupilumab discontinuation
High-dose JAK inhibitors improve disease control
Nemolizumab may have comparable efficacy to other anti-IL agents
Long-term data from phase 3 trials confirms the durable efficacy for upadacitinib
Dupilumab more effective than methotrexate or cyclosporine for paediatric patients
Contact allergens ubiquitous in complimentary hotel personal care products
Please login below to download this issue (PDF)